U.S. Stock Market Midday Update

Apollomics rose 12.04%. Based on recent news,

1. On July 13, Apollomics announced that it has met the market capitalization requirements of Nasdaq listing rule 5550(b)(2). This achievement ensures Apollomics' continued compliance for listing on the Nasdaq capital market, addressing related issues and driving the stock price up.

2. On July 13, Apollomics released a statement confirming its compliance with Nasdaq listing requirements, further enhancing market confidence and leading to a significant increase in stock price.

3. No other significant news recently. Market confidence in the biopharmaceutical industry has strengthened.

Stocks with High Trading Volume in the Industry

AbbVie rose 2.75%. Based on recent news,

1. On July 13, Wells Fargo raised AbbVie's target price from $260 to $295, maintaining an "Overweight" rating. This news boosted market confidence and drove the stock price up.

2. On July 15, AbbVie's Skyrizi and Rinvoq grew by 31% and 23% respectively in the first quarter of 2026. This strong performance further enhanced investors' confidence in the company's future growth.

3. On July 16, AbbVie announced plans to acquire Apogee Therapeutics for $10.9 billion to strengthen its immunology business. Analysts believe this acquisition plan will help the company address the risks of future patent expirations, raising market expectations. The pharmaceutical industry has recently performed strongly, and investor sentiment is optimistic.

Gilead Sciences rose 1.10%. Based on recent key news:

1. On July 16, Gilead Sciences announced that its BDR program in Brazil will take effect on July 30, with the BDR ratio adjusted from 1:2 to 1:12, and a mandatory stock split. This adjustment may increase investor interest in the stock, driving the price up. Source: Public Technologies

2. On July 13, a FactSet survey showed that analysts raised their median EPS estimate for Gilead Sciences for 2026 from -$0.77 to -$0.74, with a target price of $165. The improvement in analysts' expectations may enhance market confidence and support the stock price increase. Source: FactSet

3. On July 16, Gilead Sciences announced a donation of drugs to support viral research projects in Africa, receiving funding support from multiple international organizations. This initiative may enhance the company's reputation in global health, indirectly driving the stock price up. Source: Public Technologies The pharmaceutical industry is active in innovative drug research and development, attracting high market attention.

Amgen rose 2.86%. Based on recent news,

1. On July 16, Citigroup analyst Geoff Meacham maintained a hold rating on Amgen and set a target price of $345 This move indicates that the market holds a cautious attitude towards Amgen's prospects, leading to a rise in its stock price.

2. On July 14, market analysis showed that although Amgen is currently rated as hold, top analysts believe there are better investment options available. This news may prompt some investors to reassess their portfolios, driving stock price fluctuations.

3. On July 13, market analysis pointed out that although Amgen was not included in the list of five stocks recommended by top analysts, its lower price-to-earnings ratio and stable oncology business make it attractive in the current market environment, driving its stock price up. Market analysts maintain a cautious stance on Amgen.

Stocks ranked among the top in industry market capitalization

Forte Pharma rose by 0.85%. Based on recent news,

1. On July 14, Simply Wall St published an article on long-term investment analysis, which, while not directly recommending buy or sell, emphasized the importance of fundamental data. This may have sparked investor interest in Forte Pharma, driving its stock price up.

2. On July 16, the market performance of Vertex Pharmaceuticals was reported, and although there is no direct correlation with Forte Pharma, the positive performance in the pharmaceutical industry may have boosted overall sector investment enthusiasm, indirectly affecting Forte Pharma's stock price.

3. On July 13, BMO Capital analyst Evan Seigerman maintained a buy rating on Vertex Pharmaceuticals and set a target price of $600. This news may have bolstered market confidence in the pharmaceutical industry, further driving up Forte Pharma's stock price. The pharmaceutical industry has performed strongly recently, enhancing investor confidence